These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27755221)

  • 1. Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine: Human Model to Assess Central and Peripheral Effects of Dosing.
    Bieck PR; Leibowitz M; Lachno DR; Ledent E; Padich R; Jhee S
    J Clin Psychopharmacol; 2016 Dec; 36(6):675-683. PubMed ID: 27755221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans.
    Kielbasa W; Lobo E
    J Clin Pharmacol; 2015 Dec; 55(12):1422-31. PubMed ID: 26011686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition.
    Kielbasa W; Pan A; Pereira A
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):377-85. PubMed ID: 25637266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects.
    Chappell JC; Eisenhofer G; Owens MJ; Haber H; Lachno DR; Dean RA; Knadler MP; Nemeroff CB; Mitchell MI; Detke MJ; Iyengar S; Pangallo B; Lobo ED
    J Clin Psychopharmacol; 2014 Feb; 34(1):9-16. PubMed ID: 24346757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles.
    Vincent S; Bieck PR; Garland EM; Loghin C; Bymaster FP; Black BK; Gonzales C; Potter WZ; Robertson D
    Circulation; 2004 Jun; 109(25):3202-7. PubMed ID: 15184278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine.
    Montoya A; Escobar R; García-Polavieja MJ; Lachno DR; Alda JÁ; Artigas J; Cardo E; García M; Gastaminza X; Gilaberte I
    J Child Neurol; 2011 Jan; 26(1):31-6. PubMed ID: 20525942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function.
    Shibao C; Raj SR; Gamboa A; Diedrich A; Choi L; Black BK; Robertson D; Biaggioni I
    Hypertension; 2007 Jul; 50(1):47-53. PubMed ID: 17515448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-related changes in prefrontal norepinephrine transporter density: The basis for improved cognitive flexibility after low doses of atomoxetine in adolescent rats.
    Bradshaw SE; Agster KL; Waterhouse BD; McGaughy JA
    Brain Res; 2016 Jun; 1641(Pt B):245-57. PubMed ID: 26774596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.
    Seneca N; Gulyás B; Varrone A; Schou M; Airaksinen A; Tauscher J; Vandenhende F; Kielbasa W; Farde L; Innis RB; Halldin C
    Psychopharmacology (Berl); 2006 Sep; 188(1):119-27. PubMed ID: 16896954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.
    Hopkins SC; Sunkaraneni S; Skende E; Hing J; Passarell JA; Loebel A; Koblan KS
    Clin Drug Investig; 2016 Feb; 36(2):137-46. PubMed ID: 26597180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure.
    Okamoto LE; Shibao C; Gamboa A; Choi L; Diedrich A; Raj SR; Black BK; Robertson D; Biaggioni I
    Hypertension; 2012 Mar; 59(3):650-6. PubMed ID: 22311903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress.
    Logan J; Wang GJ; Telang F; Fowler JS; Alexoff D; Zabroski J; Jayne M; Hubbard B; King P; Carter P; Shea C; Xu Y; Muench L; Schlyer D; Learned-Coughlin S; Cosson V; Volkow ND; Ding YS
    Nucl Med Biol; 2007 Aug; 34(6):667-79. PubMed ID: 17707807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans.
    Goldstein DS; Eisenhofer G; Stull R; Folio CJ; Keiser HR; Kopin IJ
    J Clin Invest; 1988 Jan; 81(1):213-20. PubMed ID: 3335637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on 3-methoxy-4-hydroxyphenylglycol (MHPG) and 3,4-dihydroxyphenylglycol (DHPG) levels in human urine, plasma and cerebrospinal fluids, and their significance in studies of depression.
    Tsuji M; Yamane H; Yamada N; Iida H; Taga C; Myojin T
    Jpn J Psychiatry Neurol; 1986 Mar; 40(1):47-56. PubMed ID: 3773351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.
    Udvardi PT; Föhr KJ; Henes C; Liebau S; Dreyhaupt J; Boeckers TM; Ludolph AG
    Drug Des Devel Ther; 2013; 7():1433-46. PubMed ID: 24348020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP-432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects.
    Sramek JJ; Hardy LW; Bieck P; Zamora C; Versavel M; Kharidia J; Grinnell T; Chen YL; Sullivan M; Ding H; Cutler NR
    CNS Neurosci Ther; 2016 May; 22(5):404-12. PubMed ID: 26849844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD.
    Ding YS; Naganawa M; Gallezot JD; Nabulsi N; Lin SF; Ropchan J; Weinzimmer D; McCarthy TJ; Carson RE; Huang Y; Laruelle M
    Neuroimage; 2014 Feb; 86():164-71. PubMed ID: 23933039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma dihydroxyphenylglycol (DHPG) in the in vivo assessment of human neuronal norepinephrine metabolism.
    Izzo JL; Thompson DA; Horwitz D
    Life Sci; 1985 Sep; 37(11):1033-8. PubMed ID: 4033349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Myricetin on Pharmacokinetics of Atomoxetine and its Metabolite 4-Hydroxyatomoxetine In Vivo and In Vitro.
    Lan T; Hu XX; Liang BQ; Pan WH; Zhou Q; Yuan LJ; Hu GX
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):261-268. PubMed ID: 27207674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of the plasma norepinephrine/3,4-dihydroxyphenylglycol ratio for the diagnosis of pheochromocytoma.
    Lenders JW; Willemsen JJ; Beissel T; Kloppenborg PW; Thien T; Benraad TJ
    Am J Med; 1992 Feb; 92(2):147-52. PubMed ID: 1543198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.